CORONAVIRUS (COVID-19) VACCINE-INDUCED IMMUNE THROMBOTIC THROMBOCYTOPENIA (VITT)

Course overview

CORONAVIRUS DISEASE 2019 (COVID-19), THE ILLNESS CAUSED BY SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2), CONTINUES TO HAVE SIGNIFICANT MORBIDITY AND MORTALITY WORLDWIDE, WITH MANY NATIONS ENDURING MULTIPLE OUTBREAKS OF THIS VIRAL ILLNESS. MANY VACCINES (BNT162B2, MRNA-1273, AD26.COV2.S, AND CHADOX1 NCOV-19 ) HAVE BEEN DEVELOPED AT AN UNPRECEDENTED SPEED USING DISTINCTIVE TECHNOLOGIES TO PREVENT COVID-19. SEVERAL CASES OF UNCOMMON THROMBOTIC EVENTS ASSOCIATED IN COMBINATION WITH THROMBOCYTOPENIA WERE OBSERVED IN PATIENTS WHO WERE VACCINATED WITH CHADOX1 NCOV-19 VACCINES. THIS ARTICLE WILL HIGHLIGHT THE ROLE OF THE INTERPROFESSIONAL TEAM IN THE MANAGEMENT OF PATIENTS WITH THE RARE SYNDROME OF VACCINE-INDUCED IMMUNE THROMBOTIC THROMBOCYTOPENIA (VITT).